PhaseV debuted AI Conductor, an AI-driven clinical development offering aimed at automating trial execution tasks from protocol development through regulatory submission readiness. The platform is intended to harmonize data across studies, enforce document consistency, support ICH E9 compliance, and generate case report artifacts. PhaseV said the tool integrates into its existing AI-based clinical trial platform and is designed to reduce the “disconnected manual tasks” that slow submissions and operational readiness. The launch follows the company’s prior €50 million funding and is positioned as part of a broader wave of AI trial tooling. In the market context, the new release highlights increasing vendor competition in clinical ops automation as sponsors seek faster trial documentation cycles and stronger compliance traceability.